Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options. Read the Clinical Practice article “Cancer of Unknown

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer #Onco404 #Cancer #Kanser #MedX #CancerAwareness #Chemokine #ImmuneSystem #ImmuneResponse #TumorImmunity #Vocabulary

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic NSCLC: final, 6-year outcomes from CheckMate 9LA in ESMO Open. Durable OS benefit as compared to platinum-based CT, no new safety signals. esmoopen.com/article/S2059-…

🚨 BREAKING: HARMONi Trial Results Ivonescimab + chemo delivers a significant PFS benefit in EGFR-mutant NSCLC after EGFR TKI failure! 📊 PFS HR: 0.52 (p < 0.00001) 🧬 OS trending positive: HR 0.79 (p = 0.057)- not mature. 🌍 Global study with 38% Western pts 🛡 Manageable

OptiTROP-Lung03 published on The BMJ: sacituzumab tirumotecan (sac-TMT) versus docetaxel for previously treated EGFR-mutated advanced NSCLC sac-TMT vs docetaxel ORR: 45% vs 16% PFS: 6.9 vs 2.8 months OS: NR, HR=0.49 (data also presented at #ASCO25) bmj.com/content/389/bm…

For readers interested in bispecific antibodies in oncology, here's a comprehensive review nature.com/articles/s4157… rdcu.be/eqxm5

🧬 TWEETORIAL/X'torial: Why Every Rare Cancer Patient Deserves Molecular Profiling 🧬 1/15 🚨 Here's a shocking fact: Rare cancers make up 25% of ALL cancer cases, yet most patients never get the molecular testing that could save their lives. 👉In our policy & practice paper -

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #Oncology #CancerAwareness #InvestigationalNewDrug #IND #FDA #ClinicalTrials #Vocabulary

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #Oncology #CancerAwareness #CancerCare #MedX #ParaneoplasticSyndrome #PNS #Vocabulary

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #Oncology #GeriatricOncology #Oncogeriatrics #CancerCare #MedX #MedTwitter #Vocabulary

The Impact of Smoking on Nivolumab Outcomes in Renal Cell Carcinoma: Real-World Data from the Turkish Oncology Group #KidneyCancer Consortium academic.oup.com/oncolo/advance… This retrospective study from the Turkish Oncology Group Kidney Cancer Consortium found that current smoking